NEW YORK, NY / ACCESSWIRE / January 7, 2019 / Traders News Source, aleading independent equity research and corporate access firm focused on smalland mid-cap public companies is issuing a comprehensive report on Lexicon Pharmaceuticals, Inc.(NASDAQ: LXRX), a biopharmaceutical company that is applying gene science, based on Nobel Prize-winning technology, to discover and develop precise medicines for patients with serious, chronic conditions.
The company has two products leading its pipeline. XERMELO was approved in Australia in September for the treatment of carcinoid syndrome diarrhea. In September, clinical data for sotagliflozin were presented at the European Association for the Study of Diabetes.
More about the upcoming FDA dates, analysts report and target READ MORE
Copyand paste to your browser may be required to view the report - https://tradersnewssource.com/lexicon/
Through its Genome5000â„¢ program, Lexicon scientists have studied the role and function of nearly 5,000 genes over the last 20 years and have identified more than 100 protein targets with significant therapeutic potential in a range of diseases.
The FDA accepted the NDA for sotagliflozin on May 22, 2018. The NDA included data from the in Tandem clinical trial program, which includes three Phase 3 clinical trials assessing the safety and efficacy of sotagliflozin in approximately 3,000 adults with inadequately controlled type 1 diabetes.
The company commented on recent topline Phase I results; "Results from our Phase 1 studies build on previously reported promising preclinical data for LX2761 and confirm the drug candidate’s unique preclinical profile as a potent, gastrointestinal tract-selective SGLT1 inhibitor," said Praveen Tyle, Ph.D., executive vice president of Research and Development. "We are evaluating next steps for this compound and look forward to providing updates in the future."
Reviewthe LXRX pipeline, near-term catalysts and much more READ MORE
Copyand paste to your browser may be required to view the report - https://tradersnewssource.com/lexicon/
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
CONTACT: editor@tradersnewssource.com
SOURCE: Traders News Source